McNall-Knapp RY - Search Results

1

Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.

Aguilera D, Mazewski C, Fangusaro J, MacDonald TJ, McNall-Knapp RY, Hayes LL, Kim S, Castellino RC. Aguilera D, et al. Childs Nerv Syst. 2013 Apr;29(4):589-96. doi: 10.1007/s00381-012-2013-4. Epub 2013 Jan 8. Childs Nerv Syst. 2013. PMID: 23296323 Free PMC article.

2

Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.

Bonney PA, Santucci JA, Maurer AJ, Sughrue ME, McNall-Knapp RY, Battiste JD. Bonney PA, et al. Among authors: mcnall knapp ry. J Clin Neurosci. 2016 Apr;26:161-3. doi: 10.1016/j.jocn.2015.10.022. Epub 2016 Jan 14. J Clin Neurosci. 2016. PMID: 26777082

3

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.

Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K. Wagner LM, et al. Pediatr Blood Cancer. 2007 Feb;48(2):132-9. doi: 10.1002/pbc.20697. Pediatr Blood Cancer. 2007. PMID: 16317751

4

Reducing irinotecan-associated diarrhea in children.

Wagner LM, Crews KR, Stewart CF, Rodriguez-Galindo C, McNall-Knapp RY, Albritton K, Pappo AS, Furman WL. Wagner LM, et al. Pediatr Blood Cancer. 2008 Feb;50(2):201-7. doi: 10.1002/pbc.21280. Pediatr Blood Cancer. 2008. PMID: 17570704 Review.

5

Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.

McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH. McNall-Knapp RY, et al. Pediatr Blood Cancer. 2010 Jul 1;54(7):909-15. doi: 10.1002/pbc.22460. Pediatr Blood Cancer. 2010. PMID: 20405511 Clinical Trial.

6

A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.

Su JM, Murray JC, McNall-Knapp RY, Bowers DC, Shah S, Adesina AM, Paulino AC, Jo E, Mo Q, Baxter PA, Blaney SM. Su JM, et al. Among authors: mcnall knapp ry. Pediatr Blood Cancer. 2020 Jun;67(6):e28283. doi: 10.1002/pbc.28283. Epub 2020 Apr 14. Pediatr Blood Cancer. 2020. PMID: 32285998 Clinical Trial.

7

Persistent psychosocial problems in children who develop posterior fossa syndrome after medulloblastoma resection.

Wolfe-Christensen C, Mullins LL, Scott JG, McNall-Knapp RY. Wolfe-Christensen C, et al. Pediatr Blood Cancer. 2007 Oct 15;49(5):723-6. doi: 10.1002/pbc.21084. Pediatr Blood Cancer. 2007. PMID: 17066468

8

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK; Children’s Oncology Group. Baker DL, et al. N Engl J Med. 2010 Sep 30;363(14):1313-23. doi: 10.1056/NEJMoa1001527. N Engl J Med. 2010. PMID: 20879880 Free PMC article. Clinical Trial.

9

H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.

Vuong HG, Le HT, Ngo TNM, Fung KM, Battiste JD, McNall-Knapp R, Dunn IF. Vuong HG, et al. J Neurooncol. 2021 Dec;155(3):225-234. doi: 10.1007/s11060-021-03890-9. Epub 2021 Nov 18. J Neurooncol. 2021. PMID: 34796414 Review.

10

Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas.

Vuong HG, Ngo TNM, Le HT, Jea A, Hrachova M, Battiste J, McNall-Knapp R, Dunn IF. Vuong HG, et al. Front Oncol. 2022 Mar 18;12:858148. doi: 10.3389/fonc.2022.858148. eCollection 2022. Front Oncol. 2022. PMID: 35371982 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters